- Home
- DD vs ONC Comparison
DD vs ONC Comparison
Compare DD & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DD
- ONC
- Stock Information
- Founded
- DD 2015
- ONC 2010
- Country
- DD United States
- ONC Switzerland
- Employees
- DD N/A
- ONC N/A
- Industry
- DD Major Chemicals
- ONC Biotechnology: Pharmaceutical Preparations
- Sector
- DD Industrials
- ONC Health Care
- Exchange
- DD Nasdaq
- ONC Nasdaq
- Market Cap
- DD 29.3B
- ONC 31.5B
- IPO Year
- DD N/A
- ONC N/A
- Fundamental
- Price
- DD $70.45
- ONC $288.18
- Analyst Decision
- DD Buy
- ONC Strong Buy
- Analyst Count
- DD 12
- ONC 9
- Target Price
- DD $86.50
- ONC $335.78
- AVG Volume (30 Days)
- DD 3.2M
- ONC 465.2K
- Earning Date
- DD 08-05-2025
- ONC 08-06-2025
- Dividend Yield
- DD 2.33%
- ONC N/A
- EPS Growth
- DD N/A
- ONC N/A
- EPS
- DD N/A
- ONC N/A
- Revenue
- DD $12,607,000,000.00
- ONC $4,562,002,000.00
- Revenue This Year
- DD $6.39
- ONC $865.19
- Revenue Next Year
- DD $4.41
- ONC $21.12
- P/E Ratio
- DD N/A
- ONC N/A
- Revenue Growth
- DD 4.55
- ONC 47.33
- 52 Week Low
- DD $53.77
- ONC $170.99
- 52 Week High
- DD $90.06
- ONC $313.29
- Technical
- Relative Strength Index (RSI)
- DD 42.51
- ONC N/A
- Support Level
- DD $68.98
- ONC N/A
- Resistance Level
- DD $76.00
- ONC N/A
- Average True Range (ATR)
- DD 1.97
- ONC 0.00
- MACD
- DD -0.66
- ONC 0.00
- Stochastic Oscillator
- DD 16.08
- ONC 0.00
About DD DuPont de Nemours Inc.
DuPont is a diversified global specialty chemicals company created in 2019 as a result of the DowDuPont merger and subsequent separations. Its portfolio includes specialty chemicals and downstream products that serve the electronics, water, construction, safety and protection, automotive, and healthcare industries. DuPont plans to spin off its electronics business by the end of 2025, which will be named Qnity.
About ONC BeiGene Ltd. American Depositary Shares
Founded in 2010 in Beijing and having listed on the Hong Kong exchange in 2018, BeiGene is a commercial-stage biotechnology company with global sales. It focuses on oncology therapeutics and differentiates itself from other companies with a contract research organization-free, or CRO-free strategy. BeiGene runs global clinical trials with its own team. As of 2024, its core drug is Brukinsa, a small molecule drug for various blood cancers that makes up more than 60% of BeiGene's revenue.